Pyrrole Amide Crystal Form for Stable Single-Phase Drug Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pyrrole amide compounds, such as (S)-1-(2-hydroxyethyl)-4-methyl-N-(3-fluoro-4-(methylsulfonyl)phenyl)-5-(2-(trifluoromethyl)phenyl)-1H-pyrrole-3-carboxamide, are difficult to obtain in a pure crystalline form with a single microstructure, affecting their stability, solubility, and bioavailability, which are crucial for effective mineralocorticoid receptor antagonism.
Innovation Solution
A crystalline form of the compound (Form I) with specific X-ray powder diffraction peaks at designated 2θ angles and characterized by good stability, pharmacokinetics, and low hygroscopicity is developed, suitable for pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If various methods are used to obtain crystalline form of the compound, then the stability and pharmacokinetic properties are improved, but it is difficult to obtain a pure crystalline form with a single microstructure
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including solvent type (ethyl acetate, isopropanol, ethanol, acetone), temperature (room temperature, 40°C, 60°C, 80°C), and pH adjustments to transform the compound from amorphous form to specific crystalline forms (Form I, Form II, Form III), each with distinct stability and pharmacokinetic properties
Solution Approach 2:
The patent uses solvents as intermediary substances to facilitate the transformation from amorphous to crystalline form. Specific solvents like ethyl acetate, isopropanol, ethanol, and acetone act as mediators that enable controlled crystallization, with each solvent producing different crystalline forms with unique microstructures and properties
2Ease of manufacture
If the compound is used in amorphous form, then the preparation is simpler, but the stability and bioavailability are reduced
Solution Approach 1:
The patent exploits phase transitions by converting the compound from amorphous phase to crystalline phase through controlled crystallization processes. This phase transition significantly improves stability and bioavailability while maintaining practical manufacturability through straightforward procedures like solvent addition and temperature control
3Adaptability or versatility
If multiple crystalline forms are obtained, then the solubility and dissolution properties can be optimized, but the drug quality control becomes more complex
Solution Approach 1:
The patent segments the crystalline forms into distinct, well-characterized categories (Form I, Form II, Form III) with unique diffraction patterns and properties. Each form is independently characterized and can be selectively produced through specific crystallization conditions, enabling precise quality control and optimal solubility selection for different therapeutic needs
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline form I exhibits improved stability, solubility, and bioavailability, making it suitable for treating conditions like hyperaldosteronism, hypertension, and renal diseases, with a simple and reproducible preparation method suitable for industrial production.
Implementation Method 1
The crystalline form of the present invention is characterized in that the X-ray powder diffraction pattern has diffraction peaks at the following 2θ angles: 14.45°±0.2°, 17.04°±0.2°, 19.35°±0.2°, 22.51°±0.2°, 24.78°±0.2°
Implementation Method 2
the X-ray powder diffraction pattern has diffraction peaks at the following 2θ angles
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided are a crystalline form of a pyrrole amide compound, a preparation method therefor and a use thereof, and also provided is pharmaceutical composition comprising the crystalline form. In particular, the crystalline form or the pharmaceutical composition can be used to treat and prevent diseases such as hyperaldosteronism, diabetic nephropathy, hypertension, heart failure (comprising chronic heart failure, etc.), sequelae of myocardial infarction, liver cirrhosis, renal failure, and stroke.